Index

accessible clinical record, failure to maintain 32
acetylcysteine 160
advance health care directive 205–6
agitation 112, 150, 195, 238
agnosia 25
AIDS-defined illness 170, 171
alprazolam 115
alternative medicine, techniques 41
objective judgement, clinician, patients 41
aluminium hydroxide 78
Alzheimer’s disease 148
amantadine 46, 136
amisulpride 190
amitriptyline 107, 117, 138, 165
amphotericin 78
amyotrophic lateral sclerosis (ALS) palliative approach 155
supportive phase, palliation issues bladder and bowel difficulties 161
drooling 161
muscle weakness 158
pain 163
progressive hypoxia 158–60
psychological difficulties 162
sleep disturbance 161
speech difficulty 160
swallowing dysfunction 160
telling bad news advance directives 157
end-of-life discussion 156–7
supervision of care 157–8
terminal phase, palliation issues anxiety 164
carers 165
depression and frustration 164
euthanasia requests 165
fear of choking 164
hypoxia and drowsiness, respiratory failure 163
pain, immobile limbs 163–4
secretions accumulation 164
anorexia 86
anticonvulsants 107
antidepressants 107
anti-dysrhythmics 107
anti-emetic medications 81–2
anxiety 115–16
aphasia 25
apomorphine 146
appropriate therapy regimens 16
administration, medication 16
ceasing unnecessary medications 36
drugs infusion 37
apraxia 25
assisted ventilation 72–4
tracheostomy 73–4
atropine 76, 161
autonomous pain 109
baclofen 51, 53, 55, 122, 158
bad news of ALS, telling 156–7
supportive phase 28
terminal phase 28–9
behaviour therapy 46
benzhexol 54, 60, 62, 69, 82
benztpoline 54, 60, 62, 68, 82, 121
bereavement care 24
bereavement 118–19
best answer: innovation, experiment 36
biperiden 62
bisacodyl 84
botulinum toxin 52–3, 69
bowel dysfunction bowel incontinence 84–5
constipation 82–4

© Cambridge University Press  www.cambridge.org
bowel dysfunction (cont.)
  diarrhoea 84–5
  urine and bowel management, spinal injury 85
bowel incontinence 84–5
bromocriptine 60, 144
bulbar symptoms
  drooling 68–9
  dysphagia 65–7
  fear of choking 67
  impaired speech 65
bupivacaine 110
cabergoline 144
caffeine 46
cancer
  care, different trajectories 6
  and neurological disease 6
  candida infection 78
  cannabis 87
capsaicin 122, 138
carbamazepine 54, 58, 60, 107, 158, 169
carers support 37
  advocacy 38
  bereavement care 40
  carer fatigue, burnout 39
  education 38
  emotional support 39
  practical help 37
  respite 38
carbidopa 61, 163
carbidopa–levodopa 117, 144
central pain 108–9
  cognitive impairment 111–12
  coma 209
  common themes
    holism 33–4
    recording, observations 34
    complementary medicine 40
  consent and decision-making 203–4
  constipation 82–4
  coordinated care plan 20, 21, 228
  cough 74–5
  assistance 74–5
  suppression 75
  Creutzfeldt–Jakob disease (CJD)
    palliation issues
      myoclonus 169
      neuropathic pain and dysaesthesia 169
      nutrition and hydration 169
      post-mortem examination 169
      psychological disorders 168
  cyclizine 79, 81
dantrolene 51
danzepine 113
decision-making, nodal points
  bereavement care 24
  ‘do not resuscitate order’ 23
palliative care team 23
palliative interventions 21
palliative management approach 20–1
terminal phase, onset timing 22
delirium 104, 112, 172
dementia 148
symptom management, palliation system
dignity, maintenance 152
ethical issues 151
family support 149
medications 149
psychological difficulties 150–1
symptom recognition 150
terminal phase, palliation issues
decision-making 153–4
feeding issues 153
post-mortem examination 154
prognosis 152–3
symptom recognition 153
demyelinating disease
diagnosis and prognosis 132–3
supportive phase, palliation issues
alternative medicine, usage 135
bladder dysfunction 135–6
bowel dysfunction 138
fatigue 136
information and support 135
movement impairment 136–7
pain 137–8
prognosis uncertainty 133–4
psychosocial issues 138–9
relapses, management 34
sensory disturbances 137–8
site of care 139
teamwork importance 134–5
terminal phase, advance directives 141
terminal phase, palliation issues
bowel management 140
cognitive impairment 140
medications administration 140–1
motor impairments 139–40
skin care 140
depression 114–15
desmopressin 91
dexamethasone 79, 80, 87, 134
diazepam 51, 57, 112, 113, 107, 180, 193
dicyclomine 92
dimenhydrinate 80
disease status and prognosis, information
palliation characteristics 14
disordered consciousness, ethical issues
coma 209
locked-in syndrome (LIS) 212–14
minimally conscious state (MCS) 212
persistent vegetative state (PVS) 209–11
criteria 210
management 214–17
‘do not resuscitate order’, writing 23
decision-making, nodal points 23–4
docusate 84, 104
dolestron 82
domperidone 79, 82, 104
donepezil 145
doxepin 122
drooling 68–9
droperidol 113
dry mouth 77–8
duchenne muscular dystrophy (DMD) 178
dysphagia 65–7
management 67
neurological conditions 66
dyspnoea 70–1
dystonia 54, 62
enoxoparin 194
epidural and intrathecal drugs 109–10
esomeprazole 79
euthanasia 219
food and drink, refusal 219
heavy sedation 220
intensive symptom management 220
life-sustaining treatment, refraining or ceasing 219–20
physician-assisted suicide 220–2
falls 63–4
family members, support
physical support 15–16
psychological support 14–15
famotidine 78
fatigue 45–6
differential diagnosis 45
therapies 46
fear of choking 68, 164
fentanyl 110
fever 120
flecainide 107
fluconazole 78
flumazenil 113
fluoxetine 115, 136, 164
future clinical pathway see coordinated care plan
gabapentin 107
galantamine 149
gastric-oesophageal reflux 78–9
gastrointestinal symptoms:
bowel dysfunction 82–5
candida infection 78
dry mouth 77–8
dysphagia 65–7
gastric-oesophageal reflux 78–9
nausea and vomiting 79–82
nutrition and hydration 86–8
glycopyrrolate 69, 76, 161, 164
grief 118–19
haloperidol 81, 104, 113, 114, 169, 172, 192, 199
headache 123–4
hemifacial spasm 62
hexamine hippurate 90
hiccups 122–3
highly active antiretroviral therapy (HAART) 170–4
HIV-AIDS
consistent supervision 173–4
HIV neurology, management dilemma 177
initial phase 170–1
supportive phase, palliation issues
fatigue 173
neuropathic pain 172
psychiatric issues 172
symptom management 173
treatment and co-morbidities 171–2
terminal phase, palliation issues
anxiety and depression 176
dementia 175
family tension 176
fatigue 176
multiple pathologies 176
pain management 175–6
palliative approach, transition 174–5
site of care 175
staff attitudes and protection 175
home care, practical aspects
advantages 228
carers
common questions 227–8
education 227
home environment 226–7
necessary support 225–6
record importance 228–9
hospice and palliation
in advanced cancer 4–5
Huntington’s disease
supportive care, palliation issues 187–8
symptoms 186–7
terminal phase, palliation issues
dementia 190
feeding difficulties 190
motor disorder 188–9
psychological issues 189
safe environment, creating 189
terminal events 190
hydration 88
hydromorphone 101, 110
nociceptive pain 101
hyoscine hydrobromide 68, 76, 167
hyperhidrosis see sweating
hyperventilation 71–2
 nocturnal 72
hyoscine hydrobromide 80
imipramine 91, 161
impaired speech 65
speech pathology see speech therapy
ineffective networking 30–1
insomnia 116–18
intrathecal baclofen 52
involuntary movements
myoclonus 59
restless legs 60–1
tremor 59–60
ketamine 109, 110, 167
ketocoazol 78
lactulose 83
lamotrigine 107
lansoprazole 79
laxatives 83–4
levodopa 163
lidocaine 107
lignocaine 75, 107
lithium carbonate 163
locked-in syndrome (LIS) 212–14
loperamide 85, 173
lorazepam 115, 189
macrogol 83
magnesium hydroxide 78
magnesium oxide 83
magnetic resonance imaging (MRI) 9
mane and morphine sulphate 169
medroxyprogesterone acetate 87
megestrol acetate 87
melatonin 117
menthol 121
methylphenidate 46, 104, 136, 192
methylprednisolone 114
metoclopramide 79, 80, 81, 104, 123
metronidazole 85
mexiletine 107
miconazole 78
midazolam 68, 71, 84, 88, 110, 113, 114, 130, 147, 164, 180, 195, 199
minimally conscious state (MCS) 212
misoprostol 81
modafinil 46, 116
morphine 68, 71, 84, 87, 101, 110, 117, 130, 147, 164, 169, 173, 180, 195
motor neuron disease see amyotrophic lateral sclerosis
movement disorders, drug-induced 61
dystonia 61
hemifacial spasm 62
serotonin syndrome 62
tardive dyskinesia 62–3
muscle cramps 54–5
muscle tone and contraction, disorders 49
dystonia 54
muscle cramps 54–5
spasticity 50–3
muscle weakness 47, 158, 163
approaches 48
dropped head syndrome 48
supportive phase 47
terminal phase 49
muscles and movement problems 47
drug-induced 61–3
involuntary movements 59–61
muscle and contraction, disorders 49–55
seizures 55–8
syncope and fall 63–4
weakness 47–9
muscular dystrophy
supportive phase, care 178–9
terminal phase, palliation issues
anxiety 180–1
bereavement issues 181–2
facing terminal phase 181
geneic counselling 182
hypoxia 180
pain 181
site of care 181
myoclonus 59
national health planning
palliation service 230–1
nausea and vomiting 79–82
nervous system, incurable infections
Creutzfeldt–Jakob disease 168–9
HIV infection 170–7
rabies 166–7
neurological disease
care, different trajectories 6–8
conventional treatments, pathway 7
palliation management relationship 8
neurology, pain 97
pain assessment 98
pain management 98
World Health Organization ladder 98–100
neuropathic pain 96
drugs 106–7
management 105
membrane stabilizers 106
recognition and assessment 105
neuropathies 183
palliation issues
anxiety, genetic issues 185
extremities, weakness 184–5
joint and skin damage 184
multiple ancillary symptoms 185
painful neuropathy 184
nifedipine 92, 123
nitrofuradanin 90
nociceptive pain 95
baseline, breakthrough analgesic doses 103
confusion, delirium 104
constipation 104
drowsiness 104
management 100–5
myoclonus 104–5
nausea 104
opioid, starting 101–3
side-effects of opioids 104
non-invasive positive pressure ventilation (NIPPV) 72–3
nutrition
anorexia 86
nutritional support 86–8
nystatin 78
obstinate diseases
  supportive phase 5
  terminal phase 5
octreotide 173
olanzapine 113, 117, 172, 189
omeprazole 79, 81
ondansetron 80, 82
opioids 75, 102, 104
chronic pain 107–8
orphenadrine 55
oxazepam 115
oxybutynin 91, 161
oxydocodone 101
pain
  central pain 108–9
  chronic pain, opioids 107–8
difficult pain, strategies 109–10
eyearly control, importance 96–7
in neurology 97–100
neuropathic pain 105–7
nociceptive pain, management 100–5
types and mechanisms 95–6
palliation 3–4
neuroscience 8–11
origin 4
palliative care 3–4
palliative management 3–4
therapies 11
palliation, characteristics
bereavement support 18–19
comprehensive care 16
continuity care 16–17
deterioration, recognition 18
disease status and prognosis, information 14
family members
physical support 14–16
psychological support 14–15
patient-centred 12–13
work and networking 17–18
palliation practice
common themes 33–41
palliation service, characteristics
education 232–3
national health planning 230–1
organization, population basis 231
palliation teams 231–2
palliative care 3–4
palliative care team, referral 23
palliative interventions 21
palliative management 3–4
approach
  coordinated care plan 20, 21
in neurology 5
palliative management, common deficiencies
accessible clinical record
maintenance failure 32
ineffective networking 30–1
poor communication
bad news 28–9
communication aids 26–7
general principles 27–8
poorly developed teamwork 31–2
rigid professional boundaries 29–30
palliative management, neurology
obstinate diseases 5
pantoprazole 79
pergolide 60, 61, 144
persistent vegetative state (PVS) 209
criteria 210
management
  family as patient 215
  nutritional support, withdrawal 216–17
terminal phase 215–16
phenobarbitone 58, 59, 196
phenytoin 57, 58
physician-assisted suicide 220–2
Index

poor communication 28–9
communication aids 26
communication, general principles 27–8
impaired communication 25
palliative management 25
practice of palliation see palliative management
pramoxine hydrochloride 121
pressure ulcer pain, local opioids 109
primidone 60
prochlorperazine 81
promethazine hydrochloride 80
propantheline 91, 121
proxy decision-making 207–8
pruritis 121–2
pyrexia see fever
quinine 53, 158
rabeprazole 79
rashes 166
palliation issues
adequate sedation 167
continuous supervision 167
oral secretion, reduction 167
ranitidine 78
recording, observations 34–6
analogue scales 34–5
symptoms 35
referred medications 242–51
refusing treatment, right to 203–4
respiratory symptoms
assisted ventilation 72–4
cough 74–5
dyspnea 70–1
hypoventilation 71–2
retained secretions 75–6
restless legs 60–61
restlessness 112, 114, 130, 238
retained secretions, respiratory symptoms
death rattle 75–76
rigid professional boundaries 29–30
rigidity 54
riluzole 155
risperidone 117, 172, 189
rivastigmine 145
Robert Wood Johnson Foundation 156
salbutamol 74
saliva 68
seizures 55
generalized seizures 55
I-V benzodiazepine 57
partial seizures 55
supportive phase
management 57–58
neurological condition 57
pre-existing epilepsy 56
prophylactic treatment 58
status epilepticus 57
terminal phase 58
senna 84, 104
serotonin syndrome 62
sertraline 115, 116
sexual dysfunction 93–94
sildenafil 93
sleep difficulty see insomnia
sodium phenytoin 107
sodium valproate 107
sorbitol 83
spasticity
armamentarium 51–2
botulinum toxin 52–3
supportive phase 50–2
terminal phase 53
speech therapy 65
status epilepticus 56
sweating 120–1
syncope 63
tardive dyskinesia 62–3
teamwork
networking
palliation characteristics 17–18
poorly developed 31–2
temazepam 61, 115, 117
terminal sedation 218
tetrazenepine 189, 190
tetrahydrocannabinol
spasticity 52
thioridazine 113, 121, 192
tinidazole 85
tizanidine 51
topiramate 61
tramadol 100
traumatic brain injury
and spinal injury 197–9
supportive phase, palliation issues
terminal phase, palliation issues
caregiver fatigue 198
Index

traumatic brain injury (cont.)
cognitive and psychological impairment 198
death causes 198–9
family members support 199
financial matter 197–8
guardianship issues 199
life support, withdrawal 199
multiple symptoms 198
sedation 199
site of care 197

tremor
essential tremor 60
intention tremor 60
resting tremor 59–60
trimethoprim 90
tropisetron 80, 82

urGENCY and bladder spasm 91–2
urinary incontinence 92–3
urinary retention 90–1
urine and bowel management
  in spinal injury 85
urological symptoms 89
  sexual dysfunction 93–4
urgency and bladder spasm 91–2
urinary incontinence 92–3
urinary retention 90–1
valproate 58, 59
venlafaxine 121
zolpidem 162
zuclopenthixol acetate 113